secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001193125-26-029540
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics names Sarah Williams as VP, Controller and PAO; CFO Lucy Day salary reduced from Apr 2026
--------------------------------------------------------------------------------

- Sarah Williams appointed VP, Controller and Principal Accounting Officer, effective Feb 1, 2026.
- Lucy Day remains CFO; base salary reduced to $223,600 from April 1, 2026 (current $335,400 until Mar 31).
- Williams receives annual base salary of $310,000 with target annual bonus of 30% of base.
- Day's severance eligibility reduced to 50% of plan if terminated after April 1, 2026 (non-CIC).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526029540/0001193125-26-029540-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000119312526029540/d84725d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-029540

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer